Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $121.3 million.

  • Silence Therapeutics' Cash & Equivalents rose 26.96% to $102.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 26.96%. This contributed to the annual value of $121.3 million for FY2024, which is 76.38% up from last year.
  • Latest data reveals that Silence Therapeutics reported Cash & Equivalents of $121.3 million as of FY2024, which was up 76.38% from $68.8 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Cash & Equivalents ranged from a high of $121.3 million in FY2024 and a low of $35.2 million during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $68.8 million (2023), whereas its average is $86.0 million.
  • Per our database at Business Quant, Silence Therapeutics' Cash & Equivalents skyrocketed by 187.04% in 2021 and then tumbled by 32.95% in 2022.
  • Over the past 5 years, Silence Therapeutics' Cash & Equivalents (MRY) stood at $35.2 million in 2020, then skyrocketed by 187.04% to $101.2 million in 2021, then tumbled by 32.95% to $67.8 million in 2022, then increased by 1.40% to $68.8 million in 2023, then skyrocketed by 76.38% to $121.3 million in 2024.
  • Its last three reported values are $121.3 million in FY2024, $68.8 million for FY2023, and $67.8 million during FY2022.